Britain and America have signed a landmark commercial pact that will maintain no duties on UK drug shipments entering the US market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has agreed to increase spending on drugs through the NHS. This move secures that duties on these key products will be held at zero for a period of three years.
This development follows earlier warnings to hike tariffs on branded drug imports, with potential rates floated up to 100%.
"This agreement with the Britain strengthens the global environment for new treatments and brings long-overdue equity to American-British drug exports," a release declared.
Commercial Impact
Drugs represent one of the UK's biggest goods shipped to the United States, which is easily the largest market for large companies like GSK and AstraZeneca.
Export figures indicate that in the year to the end of September, the UK shipped medicines valued at billions to the US. This figure accounted for 17.4% of all goods exports in that span.
"This guarantee safeguards work, increases funding and paves the way for the UK to emerge as a international leader for medical research," a minister commented.
Specific UK Commitments
The agreement involves several specific changes from the UK:
- Price Threshold Increase: The UK will lift the cost ceiling at which it judges new therapies to be unaffordable by a quarter.
- Boosted Medicine Funding: There is a goal to double overall health service expenditure on treatments from 0.3 percent of the national economy to 0.6% over the coming ten years.
- Rebate Cap: The sum drug companies must pay back to the NHS to prevent overspending will be restricted at 15%. Last year, rebates topped 20%.
Recent Tensions
The deal comes amid a ongoing dispute between the sector and the British authorities over drug pricing and NHS adoption.
These tensions were exacerbated by assertions that American patients were paying a premium for the identical medicines than consumers in the UK and Europe.
Over the last 18 months, several large manufacturing plans in the UK have been delayed or scrapped, while multi-billion-dollar expansions have been pledged toward American operations.
The Science Minister acknowledged that the NHS must increase expenditure on treatments, noting that its spending on drugs had shrunk as a percentage of its overall budget over the last ten years.
